|Dr. Garo H. Armen Ph.D.||N/A||N/A||64|
|Dr. Alexander K. Arrow M.D., CFA||106.55k||N/A||46|
|Dr. Dalia Barsyte Ph.D.||N/A||N/A||N/A|
|Dr. David A. Lovejoy Ph.D.||N/A||N/A||N/A|
|Ms. Christina Fam Faragalla||N/A||N/A||N/A|
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.
Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.